Search Results - "Segal, N H"

A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas by Lee, J K, Capanu, M, O'Reilly, E M, Ma, J, Chou, J F, Shia, J, Katz, S S, Gansukh, B, Reidy-Lagunes, D, Segal, N H, Yu, K H, Chung, K-Y, Saltz, L B, Abou-Alfa, G K

“…Background: This study evaluated the addition of sorafenib to gemcitabine and cisplatin in biliary adenocarcinoma first-line therapy. Methods: Patients with…”
Get full text

Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma by Yoon, S. S., Segal, N. H., Olshen, A. B., Brennan, M. F., Singer, S.

“…Background: Tumor angiogenesis, or new blood vessel formation, is regulated by a balance between pro-angiogenic factors such as vascular endothelial growth…”
Get full text

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor by Belum, V.R, Benhuri, B, Postow, M.A, Hellmann, M.D, Lesokhin, A.M, Segal, N.H, Motzer, R.J, Wu, S, Busam, K.J, Wolchok, J.D, Lacouture, M.E

“…Abstract Background Dermatologic adverse events (AEs) are some of the most frequently observed toxicities of immune-checkpoint inhibitor therapy, but they have…”
Get full text

Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer by Ambrosini, M, Rousseau, B, Manca, P, Artz, O, Marabelle, A, André, T, Maddalena, G, Mazzoli, G, Intini, R, Cohen, R, Cercek, A, Segal, N H, Saltz, L, Varghese, A M, Yaeger, R, Nusrat, M, Goldberg, Z, Ku, G Y, El Dika, I, Margalit, O, Grinshpun, A, Murtaza Kasi, P, Schilsky, R, Lutfi, A, Shacham-Shmueli, E, Khan Afghan, M, Weiss, L, Westphalen, C B, Conca, V, Decker, B, Randon, G, Elez, E, Fakih, M, Schrock, A B, Cremolini, C, Jayachandran, P, Overman, M J, Lonardi, S, Pietrantonio, F

“…POLE and POLD1 proofreading deficiency (POLE/D1pd) define a rare subtype of ultramutated metastatic colorectal cancer (mCRC; over 100 mut/Mb). Disease-specific…”
Get more information

Changes in the multidisciplinary management of rectal cancer from 2009 to 2015 and associated improvements in short‐term outcomes by Roxburgh, C. S. D., Strombom, P., Lynn, P., Cercek, A., Gonen, M., Smith, J. J., Temple, L. K. F., Nash, G. M., Guillem, J. G., Paty, P. B., Shia, J., Vakiani, E., Yaeger, R., Stadler, Z. K., Segal, N. H., Reidy, D., Varghese, A., Wu, A. J., Crane, C. H., Gollub, M. J., Saltz, L. B., Garcia‐Aguilar, J., Weiser, M. R.

“…Aim Significant recent changes in management of locally advanced rectal cancer (LARC) include preoperative staging, use of extended neoadjuvant therapies and…”
Get full text

Prospective validation of prognostic scores to improve patient selection for immuno-oncology trials by Massard, C, Segal, N H, Cho, D C, Papadimitrakopoulou, V A, Rizvi, N A, Cho, B C, Yu, L, Yang, H, Hsieh, H-J, Zhang, J, Zhao, W, Gao, G, Guo, X, Abdullah, S, Englert, J, Soria, J-C, Dar, M, Roskos, L, Ferte, C, Antonia, S J

Get full text

Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC) by Argilés, G., Saro, J., Segal, N.H., Melero, I., Ros, W., Marabelle, A., Rodriguez, M.E., Albanell, J., Calvo, E., Moreno, V., Cleary, J.M., Eder, P., Paz-Ares, L., Hurwitz, H., Bacac, M., Perro, M., Bouseida, S., Sandoval, F., Sabanes Bove, D., Sreckovic, S., Jamois, C., Silva, A., Klein, C., Umana, P., Karanikas, V., Tabernero, J.

Get full text

Comparing metastatic (M) young onset (YO) colorectal cancer (CRC) with average onset (AO): Do they differ clinically and genetically? by Dos Santos Fernandes, G., Chatila, W., Yaeger, R., Mendelsohn, R., Stadler, Z., Segal, N.H., Varghese, A., Reidy, D., Diaz, L., Shia, J., Vakiani, E., Hechtman, J., Schultz, N., Berger, M., Hyman, D., Solit, D., Saltz, L., Garcia Aguilar, J., Cercek, A.

Get full text

BCL-2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell by Segal, N H, Cohen, R J, Haffejee, Z, Savage, N

“…Prostatic adenocarcinoma has a divergent response to androgen ablation and a varied long-term prognosis. BCL-2 is a proto-oncogene that prevents programmed…”
Get more information

603PA phase Ib study of the safety and efficacy of atezolizumab (atezo) + bevacizumab (bev) + cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC) by Bendell, J, Lieu, C, Raghav, K P S, Argilés, G, Cubillo, A, Qu, X, Yan, Y, Merchant, M, Zeuner, H, Gallo, J D, Segal, N H

“…Abstract Background mCRC is a non-immunogenic tumour type with poor response to checkpoint inhibitors, hypothetically due to low tumour T-cell levels and…”
Get full text

Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC) by Antonia, S.J., Brahmer, J.R., Khleif, S., Balmanoukian, A.S., Ou, S.-H.I., Gutierrez, M., Kim, D.-W., Kim, S.-W., Ahn, M.-J., Leach, J., Jamal, R., Jaeger, D., Jerusalem, G., Jin, X., Gupta, A., Antal, J., Segal, N.H.

Get full text

Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort by Segal, N.H., Ou, S.-H.I., Balmanoukian, A.S., Massarelli, E., Brahmer, J.R., Weiss, J., Schoffski, P., Antonia, S.J., Massard, C., Zandberg, D.P., Maher, C., Khleif, S., Jin, X., Rebelatto, M., Steele, K., Antal, J., Gupta, A., Spreafico, A.

Get full text

439PProspective validation of prognostic scores to improve patient selection for immuno-oncology trials by Massard, C, Segal, N H, Cho, D C, Papadimitrakopoulou, V A, Rizvi, N A, Cho, B C, Yu, L, Yang, H, Hsieh, H-J, Zhang, J, Zhao, W, Gao, G, Guo, X, Abdullah, S, Englert, J, Soria, J-C, Dar, M, Roskos, L, Ferte, C, Antonia, S J

Get full text

591PComparing metastatic (M) young onset (YO) colorectal cancer (CRC) with average onset (AO): Do they differ clinically and genetically? by Dos Santos Fernandes, G, Chatila, W, Yaeger, R, Mendelsohn, R, Stadler, Z, Segal, N H, Varghese, A, Reidy, D, Diaz, L, Shia, J, Vakiani, E, Hechtman, J, Schultz, N, Berger, M, Hyman, D, Solit, D, Saltz, L, Garcia Aguilar, J, Cercek, A

Get full text

LBA-004Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC) by Argilés, G, Saro, J, Segal, N H, Melero, I, Ros, W, Marabelle, A, Rodriguez, M E, Albanell, J, Calvo, E, Moreno, V, Cleary, J M, Eder, P, Paz-Ares, L, Hurwitz, H, Bacac, M, Perro, M, Bouseida, S, Sandoval, F, Sabanes Bove, D, Sreckovic, S, Jamois, C, Silva, A, Klein, C, Umana, P, Karanikas, V, Tabernero, J

Get full text

Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative by Peggs, Karl S., Segal, Neil H., Allison, James P.

“…In this Commentary we aim to provide an overview of some specific examples of cancer therapeutics, including targeted approaches using monoclonal antibodies…”
Get full text

Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors by Segal, N.H., Infante, J.R., Sanborn, R.E., Gibney, G.T., Lawrence, D.P., Rizvi, N., Leidner, R., Gajewski, T.F., Bertino, E., Sharfman, W.H., Cooley, S., Topalian, S.L., Urba, W.J., Wolchok, J.D., Gu, X., Passey, C., McDonald, D., Aanur, P., Srivastava, S., Hodi, F.S.

Get full text

Induction chemotherapy followed by chemoradiotherapy and TME for high-risk locally advanced rectal cancer by Ding, P., Weiser, M. R., Hajj, C., Saltz, L., Segal, N. H., Goodman, K. A.

“…Abstract only…”
Get full text

Vitamin D levels and survival in colorectal cancer (CRC) by Wesa, K. M., Jacobs, G., Woo, D., Cronin, A., Segal, N. H., Coleton, M., Saltz, L., Cassileth, B. R.

“…Abstract only…”
Get full text

Surgical cytoreduction in patients with colorectal peritoneal carcinomatosis treated with contemporary chemotherapy by Gava, V. G., Reidy, D. L., Paty, P., Saltz, L., Chung, K. Y., Weiser, M. R., Temple, L. K., Segal, N. H., Moreira, L. F., Nash, G.

“…Abstract only…”
Get full text